rs515726177
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PM5PP3_ModeratePP5_Very_Strong
The NM_000098.3(CPT2):c.452G>A(p.Arg151Gln) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000136 in 1,613,842 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R151W) has been classified as Pathogenic.
Frequency
Consequence
NM_000098.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CPT2 | NM_000098.3 | c.452G>A | p.Arg151Gln | missense_variant | 4/5 | ENST00000371486.4 | NP_000089.1 | |
CPT2 | NM_001330589.2 | c.452G>A | p.Arg151Gln | missense_variant | 4/5 | NP_001317518.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CPT2 | ENST00000371486.4 | c.452G>A | p.Arg151Gln | missense_variant | 4/5 | 1 | NM_000098.3 | ENSP00000360541.3 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 151948Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000278 AC: 7AN: 251482Hom.: 0 AF XY: 0.0000441 AC XY: 6AN XY: 135918
GnomAD4 exome AF: 0.0000130 AC: 19AN: 1461894Hom.: 0 Cov.: 31 AF XY: 0.0000193 AC XY: 14AN XY: 727248
GnomAD4 genome AF: 0.0000197 AC: 3AN: 151948Hom.: 0 Cov.: 32 AF XY: 0.0000270 AC XY: 2AN XY: 74196
ClinVar
Submissions by phenotype
Carnitine palmitoyltransferase II deficiency Pathogenic:2Other:1
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Sep 27, 2022 | Variant summary: CPT2 c.452G>A (p.Arg151Gln) results in a conservative amino acid change located in the Choline/carnitine acyltransferase domain (IPR039551) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.8e-05 in 251482 control chromosomes. c.452G>A has been reported in the literature as a homozygous or compound heterozygous genotype in multiple individuals affected with Carnitine Palmitoyltransferase II Deficiency (example, Yang_1998, Thuiller_2003, Corti_2008, Joshi_2019). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no traceable variant specific experimental evidence demonstrating an impact on protein function has been reported although several publications report aggregate data supporting a loss of CPT-II enzyme activity (example, Thuiller_2003). Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 12, 2023 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 151 of the CPT2 protein (p.Arg151Gln). This variant is present in population databases (rs515726177, gnomAD 0.006%). This missense change has been observed in individual(s) with carnitine palmitoyltransferase 2 (CPT2) deficiency (PMID: 9758712, 12673791, 14605500, 21913903). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 130889). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CPT2 protein function with a positive predictive value of 80%. For these reasons, this variant has been classified as Pathogenic. - |
Carnitine palmitoyl transferase II deficiency, severe infantile form Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Apr 11, 2023 | - - |
Likely pathogenic, no assertion criteria provided | clinical testing | Counsyl | Jul 18, 2019 | - - |
Carnitine palmitoyl transferase II deficiency, myopathic form;C1833511:Carnitine palmitoyl transferase II deficiency, severe infantile form;C1833518:Carnitine palmitoyl transferase II deficiency, neonatal form;C3280160:Encephalopathy, acute, infection-induced, susceptibility to, 4 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Dec 07, 2021 | - - |
Encephalopathy, acute, infection-induced, susceptibility to, 4 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Jan 25, 2024 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 11, 2023 | Not observed at a significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 14605500, 9758712, 14615409, 21913903, 31980526, 17936304, 24398345, 12673791, 31589614, 32295037, 30897730, 33610471, 34020866) - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at